Kenox Enters into Strategic Product Development Partnership with Strides

• Partnership strengthens Strides' pipeline of nasal spray products across diverse therapeutic areas
• Kenox to provide formulation and development expertise in Orally Inhaled and Nasal Drug Products (OINDPs)
• Collaboration aims to accelerate affordable, high-quality medicines for patients in the US

PRINCETON, N.J., Sept. 9, 2025 /PRNewswire/ -- Strides Pharma Science Ltd today announced that its step-down, wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. ("Kenox"), a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).

Under the terms of the agreement, Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications. Specific product details remain confidential at this stage.

Dr. Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals Inc., stated:
"Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price. Furthermore, this milestone accelerates Kenox's growth plans."

"We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain. With continued investments in the capabilities and capacities at our US facility, these products are a natural fit within our strategy to expand into our nasal spray technology domain. Kenox's formulation and development strengths perfectly complement our manufacturing and go-to-market strengths, allowing us to accelerate our range of nasal spray offerings in the US market," said Aditya Kumar, Executive Director, Business Development, Strides Pharma Science Limited.

The partnership will advance a pipeline of nasal spray products for the US market, combining Strides' commercial strengths with Kenox's OINDP expertise to deliver affordable, high-quality therapies to patients.

About Kenox
Established in 2018 and based in Greater Princeton, NJ, Kenox specializes in pharmaceutical aerosol product development, including soft mist inhalers (SMIs), dry powder inhalers (DPIs), nebulizers, and nasal sprays. As a contract development organization, Kenox offers a wealth of expertise in formulation design, compounding, fill and finish, and testing in compliance with compendial monographs.

Contact:

Kenox - Corporate or Business Development [email protected]

About Strides
Strides, a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at www.strides.com.

Contact:

Strides – Corporate communication
Pallavi Panchmatia: +91 80 6784 0193
Email: [email protected]
Janhavi Bellare: +91 93228 54508
[email protected]
Talal Syed: +91 99876 19679
[email protected]

SOURCE Kenox Pharmaceuticals Inc.